CClinicalTrials.gg
RecruitingNCT06428643Updated Sep 21, 2026

A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities

An interventional study of Chlamydia, gonorrhea, syphilis, and HIV screening in Chlamydia, Gonorrhea and Hiv, sponsored by Tulane University. Recruiting at 1 site in United States. Open to participants aged 15 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Tulane University · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
2,322
Allocation
Not applicable
Ages
15 Years to 26 Years
Sex
All
01

Study summary

This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.

02

Conditions studied

  • Chlamydia
  • Gonorrhea
  • Hiv
  • Syphilis

Keywords

  • Screening
  • Expedited Treatment
03

Who can participate

Ages eligible
15 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Identifies as African American or Black
  • 15-26 years of age
  • Lives or spends most of their time in Orleans Parish
  • Had vaginal sex at least once
  • Provide a urine or vaginal swab
  • Not taken azithromycin or cefixime in the last 7 days

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to provide informed consent
  • Unable to speak or understand English
  • Previously enrolled in the study
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,322 participants (estimated)

Study arms

  • Experimental
    Chlamydia, gonorrhea, syphilis, and HIV screening

    Community screening of individuals for chlamydia and gonorrhea is not normally done. We are testing to see if this intervention will impact the rates of chlamydia among women.

    Other: Chlamydia, gonorrhea, syphilis, and HIV screening

Interventions

  • OtherChlamydia, gonorrhea, syphilis, and HIV screening

    Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.

05

What researchers measure

Primary outcomes

  1. Rate of chlamydia in women

    Primary outcome

    Time frame: up to 60 months

Secondary outcomes

  1. Index participant medication pickup rate

    Percentage of index participants who obtain their prescribed medication from a partnering pharmacy among all index participants who report intending to pick up the medication. Medication receipt will be determined from pharmacy billing records. Rates will be calculated monthly.

    Time frame: up to 60 months

  2. Partner medication pickup rate

    Percentage of partners who obtain their prescribed medication from a partnering pharmacy among all partners reported as intending to pick up the medication. Medication receipt will be determined from pharmacy billing records. Rates will be calculated monthly.

    Time frame: 60 months

  3. Self reported treatment of index participants and partners

    Number and percentage of index participants who report that they and all applicable partner(s) received treatment. The denominator will include index participants who provide follow-up information about their own and their partner(s)' treatment status.

    Time frame: 60 months

06

Study locations

1 of 1 sites recruiting
  • Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine
    New Orleans, Louisiana 70112, United States
    • Patricia Kissinger, PhD · Contact · kissing@tulane.edu · 504-988-7320
    • Momi Sagoe, MPH · Contact · msagoe@tulane.edu · 504-988-1049
    • Patricia Kissinger, PhD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — We will provide de-identified data to persons who submit a reasonable request with appropriate institutional approval after the primary and secondary request questions have been published.

Supporting information: Sap, Icf

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06428643
Lead sponsor
Tulane University
Collaborators
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Patricia Kissinger (Principal Investigator, Tulane University) — Principal investigator
First posted
May 24, 2024
Start date
Aug 14, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Sep 21, 2026

Study contacts

Patricia Kissinger, PhD
Contact
kissing@tulane.edu
504-988-7320

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion